Sustainable therapies by engineered bacteria. Issue 5 (11th July 2017)

• Record Type: Journal Article
• Authors: Álvarez, Beatriz; Fernández, Luis Ángel
• Other Names: Morgenroth Eberhard guestEditor.; Flemming Hans‐Curt guestEditor.; Azeredo Joana guestEditor.; Melo Luis F. guestEditor.; Espinosa Manuel guestEditor.; Whiteley Marvin guestEditor.; Briandet Romain guestEditor.
• Is Part Of: Microbial biotechnology. Volume 10:Issue 5(2017:Sep.)
• Page Start: 1057
• Page End: 1061
• Publication Date: 2017-07-11
• Subjects: Microbial biotechnology -- Periodicals; Biotechnology; Microbiology; 660.62
• DOI: 10.1111/1751-7915.12778
• Languages: English
• ISSNs: 1751-7915

Abstract

Summary: The controlled in situ delivery of biologics (e.g. enzymes, cytokines, antibodies) by engineered bacteria of our microbiome will allow the sustainable production of these complex and expensive drugs locally in the human body, overcoming many of the technical and economical barriers currently associated with the global use of these potent medicines. We provide examples showing how engineered bacteria can be effective treatments against multiple pathologies, including autoimmune and inflammatory diseases, metabolic disorders, diabetes, obesity, infectious diseases and cancer, hence contributing to achieve the Global Sustainable Goal 3: ensure healthy lives and promote well‐being for all at all ages. Abstract : The controlled in situ delivery of biologics (e.g. enzymes, cytokines, antibodies) by engineered bacteria of our microbiome will allow the sustainable production of these complex and expensive drugs locally in the human body, overcoming many of the technical and economical barriers currently associated with the global use of these potent medicines.